[HTML][HTML] Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
SH Chen, PK Dominik, J Stanfield, S Ding… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background T cell checkpoint immunotherapies have shown promising results in the clinic,
but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) …
but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) …
Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma
SH Panowski, S Srinivasan, N Tan… - Cancer Research, 2022 - AACR
CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression in normal
tissue, making it an attractive CAR T target for an immunogenic solid tumor indication. Here …
tissue, making it an attractive CAR T target for an immunogenic solid tumor indication. Here …
Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencing
T Van Blarcom, A Rossi, D Foletti, P Sundar… - Journal of molecular …, 2015 - Elsevier
The ability of antibodies to bind an antigen with a high degree of affinity and specificity has
led them to become the largest and fastest growing class of therapeutic proteins. Clearly …
led them to become the largest and fastest growing class of therapeutic proteins. Clearly …
[HTML][HTML] Direct control of CAR T cells through small molecule-regulated antibodies
S Park, E Pascua, KC Lindquist, C Kimberlin… - Nature …, 2021 - nature.com
Antibody-based therapeutics have experienced a rapid growth in recent years and are now
utilized in various modalities spanning from conventional antibodies, antibody-drug …
utilized in various modalities spanning from conventional antibodies, antibody-drug …
Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer
Y Zhang, SK Tacheva-Grigorova, J Sutton… - Clinical Cancer …, 2023 - AACR
Purpose: Small cell lung cancer (SCLC) is an aggressive disease with limited treatment
options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of …
options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of …
Design and validation of inducible TurboCARs with tunable induction and combinatorial cytokine signaling
RJ Lin, AR Nager, S Park, J Sutton, C Lay… - Cancer Immunology …, 2022 - AACR
Although cytokine support can enhance CAR T-cell function, coadministering cytokines or
engineering CAR T cells to secrete cytokines can result in toxicities. To mitigate these safety …
engineering CAR T cells to secrete cytokines can result in toxicities. To mitigate these safety …
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
T Van Blarcom, K Lindquist, Z Melton, WL Cheung… - MAbs, 2018 - Taylor & Francis
The commercial success of bispecific antibodies generally has been hindered by the
complexities associated with generating appropriate molecules for both research scale and …
complexities associated with generating appropriate molecules for both research scale and …
Epitope mapping using yeast display and next generation sequencing
T Van Blarcom, A Rossi, D Foletti, P Sundar… - Epitope Mapping …, 2018 - Springer
Monoclonal antibodies are the largest class of therapeutic proteins due in part to their ability
to bind an antigen with a high degree of affinity and specificity. A precise determination of …
to bind an antigen with a high degree of affinity and specificity. A precise determination of …
[HTML][HTML] Preclinical evaluation of ALLO-819, an allogeneic CAR T cell therapy targeting FLT3 for the treatment of acute myeloid leukemia
C Sommer, HY Cheng, YA Yeung, D Nguyen, J Sutton… - Blood, 2019 - Elsevier
Autologous chimeric antigen receptor (CAR) T cells have achieved unprecedented clinical
responses in patients with B-cell leukemias, lymphomas and multiple myeloma, raising …
responses in patients with B-cell leukemias, lymphomas and multiple myeloma, raising …
[PDF][PDF] Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
Y Zhang, S Tacheva-Grigorova, Z Melton… - Cancer …, 2020 - media.sparx-ip.net
Poster #6599 Page 1 RESEARCH POSTER PRESENTATION DESIGN © 2019 www.PosterPresentations.com
DMS-273 pituitary 0% 10% 20% 30% 40% 50% Activated T cells (41BB+CD25+) % o f C A R …
DMS-273 pituitary 0% 10% 20% 30% 40% 50% Activated T cells (41BB+CD25+) % o f C A R …